Skip to main content

In Brief This Week: Novartis; Agilent; IntegraGen; Evotec, Apeiron

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Novartis this week said that it will invest more than $600 million over the next five years to expand its global research campus in Cambridge, Mass. The Cambridge site houses the Novartis Institutes for Biomedical Research, Novartis Molecular Diagnostics, Novartis Vaccines and Diagnostics, and the US office of Novartis Venture Funds.

The company expects the investment will include adding 300 jobs, however a company spokesperson declined to provide further details.


Agilent Technologies has opened a new instruments manufacturing facility in Singapore, the firm announced today. The new facility will produce the firm's liquid chromatography/mass spectrometry instruments for the global market.


French molecular diagnostics developer IntegraGen said this week that it will open a US subsidiary based in Cambridge, Mass, on Nov. 1. The new US base will support the firm's clinical research initiatives focused on identifying children at risk of autism. IntegraGen also conducts gene discovery research and provides genotyping services to the research community.


Evotec said this week that it will apply its expertise in cellular assay development in a collaboration with Apeiron Biologics to identify potential targets for pain therapies.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.